NAD+ Precursor Therapy for Neurodegenerative Diseases

Migration, Crosslink

📖

NAD+ Precursor Therapy for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nad-precursor-therapy

📖 Wiki Page

therapeutic1336 wordssynced 2026-04-02

NAD+ Precursor Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursor Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Metabolic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NAD+ depletion, mitochondrial dysfunction, DNA damage accumulation</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Oral supplements, intravenous (clinical trials)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Clinical trials (Phase I-II)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial ID</td>
</tr>
<tr>
<td class="label">NR (Niagen)</td>
<td>NCT04044162</td>
</tr>
<tr>
<td class="label">NR</td>
<td>NCT03816084</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>NCT04078161</td>
</tr>
<tr>
<td class="label">NRPT</td>
<td>NCT03204747</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>NCT04823160</td>
</tr>
<tr>
<td class="label">NR</td>
<td>NCT04362332</td>
</tr>
</table>

...

NAD+ Precursor Therapy for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">NAD+ Precursor Therapy for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Metabolic Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NAD+ depletion, mitochondrial dysfunction, DNA damage accumulation</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Huntington's Disease</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Oral supplements, intravenous (clinical trials)</td>
</tr>
<tr>
<td class="label">Stage</td>
<td>Clinical trials (Phase I-II)</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Trial ID</td>
</tr>
<tr>
<td class="label">NR (Niagen)</td>
<td>NCT04044162</td>
</tr>
<tr>
<td class="label">NR</td>
<td>NCT03816084</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>NCT04078161</td>
</tr>
<tr>
<td class="label">NRPT</td>
<td>NCT03204747</td>
</tr>
<tr>
<td class="label">NMN</td>
<td>NCT04823160</td>
</tr>
<tr>
<td class="label">NR</td>
<td>NCT04362332</td>
</tr>
</table>

NAD+ precursor therapy involves supplementation with compounds that boost cellular NAD+ levels to counteract the age-related decline in nicotinamide adenine dinucleotide (NAD+), which is critical for mitochondrial function, DNA repair, and cellular metabolism. This therapeutic approach has emerged as a promising intervention for neurodegenerative diseases based on the well-documented decline of NAD+ levels during aging and in various neurological conditions.

Overview

Mermaid diagram (expand to render)

Mechanism of Action

NAD+ is an essential coenzyme found in all living cells that plays critical roles in: [@zhang2016]

Mitochondrial energy production: NAD+ serves as an electron carrier in the electron transport chain, facilitating ATP synthesis through oxidative phosphorylation
DNA repair: PARP (poly ADP-ribose polymerase) enzymes require NAD+ to function in base excision repair, which is crucial for neuronal survival
Sirtuin activity: SIRT1-7 deacetylases depend on NAD+ for their enzymatic function, affecting chromatin remodeling, stress resistance, and metabolism
Calcium homeostasis: NAD+ regulates calcium signaling pathways through interactions with ryanodine receptors and calcium ATPases
Immune regulation: NAD+ metabolism influences inflammatory responses through effects on T cells, [microglia](/entities/microglia), and cytokine production

Biochemical Properties

NAD+ exists in both oxidized (NAD+) and reduced (NADH) forms, with the NAD+/NADH ratio serving as a critical indicator of cellular metabolic health. In aging and neurodegenerative diseases, this ratio declines significantly, leading to: [@demarin2020]

Impaired mitochondrial respiration and ATP production

Reduced sirtuin activity and compromised stress responses

Accumulation of DNA damage due to impaired repair

Dysregulated calcium signaling and excitotoxicity susceptibility

Key Pathways Affected

Mitochondrial biogenesis: PGC-1α activation via SIRT1 requires NAD+ as a co-substrate, promoting the creation of new mitochondria

DNA repair: PARP1 activation consumes NAD+ in response to DNA damage, creating poly(ADP-ribose) polymers

[Autophagy](/entities/autophagy): NAD+ and SIRT1 regulate autophagy through AMPK activation and FoxO deacetylation

Neuroinflammation: NAD+ metabolism affects microglial activation states, promoting the anti-inflammatory M2 phenotype

Synaptic plasticity: SIRT1 regulates synaptic function through deacetylation of synaptic proteins and BDNF expression

Clinical Applications

Alzheimer's Disease

NAD+ decline contributes to mitochondrial dysfunction and neuronal death in Alzheimer's disease through multiple mechanisms:

[Amyloid-beta](/proteins/amyloid-beta) toxicity: NAD+ depletion exacerbates [amyloid-beta](/proteins/amyloid-beta)-induced mitochondrial dysfunction
[Tau](/proteins/tau) pathology: Impaired NAD+ signaling affects [tau](/proteins/tau) phosphorylation and aggregation
Neuroinflammation: Microglial activation is modulated by NAD+ metabolism

Clinical trials investigating NAD+ precursors for AD include:

NCT04044162: Nicotinamide riboside for mild cognitive impairment and Alzheimer's disease
NCT03568968: NMN supplementation for Alzheimer's disease safety and efficacy

NR and NMN supplementation may improve cognitive function through improved mitochondrial bioenergetics and reduced neuroinflammation.

Parkinson's Disease

The PINK1/Parkin mitophagy pathway requires adequate NAD+ levels for proper function:

Mitochondrial quality control: NAD+ depletion impairs parkin-mediated mitophagy
Dopaminergic neuron vulnerability: Specific sensitivity of dopaminergic [neurons](/entities/neurons) to NAD+ decline
[α-synuclein](/proteins/alpha-synuclein) pathology: NAD+ metabolism affects α-synuclein aggregation and toxicity

Clinical trials:

NCT03816084: Nicotinamide riboside for Parkinson's disease - completed showing good tolerability
NCT04436533: NAD+ and metabolic profile in Parkinson's disease

Amyotrophic Lateral Sclerosis (ALS)

NAD+ restoration may protect motor neurons through:

Energy metabolism: Supporting the high energy demands of motor neurons
DNA repair: Protecting against cumulative DNA damage in motor neurons
Glutamate excitotoxicity: Modulating glutamate signaling through SIRT1

Preclinical studies in SOD1 mouse models show promising neuroprotective effects with NAD+ precursor supplementation.

Huntington's Disease

NAD+ depletion in Huntington's disease contributes to:

Mitochondrial dysfunction: Impaired energy production in striatal neurons
Transcriptional dysregulation: SIRT1 dysfunction affects gene expression
Autophagy impairment: Reduced autophagic clearance of mutant [huntingtin](/proteins/huntingtin-protein)

Key Precursors

Nicotinamide Riboside (NR)

Boosted NAD+ levels by 40-60% in clinical trials
Naturally occurring vitamin B3 form found in milk
Well-tolerated with minimal side effects
Available as dietary supplement (Niagen™, Tru Niagen™)
Phosphorylated by NR kinases (NRK1, NRK2) to NMN

Nicotinamide Mononucleotide (NMN)

Direct NAD+ precursor, one step upstream of NR
More potent than NR in raising NAD+ levels
Currently in multiple clinical trials for safety and efficacy
May have additional benefits through activation of sirtuins
Dose: 250-500mg daily in clinical trials

Nicotinamide (NAM)

Vitamin B3 form (niacin)
Less efficient due to feedback inhibition of enzymes
Can cause flushing at higher doses
Limited brain penetration compared to NR/NMN

Nicotinamide Mononucleotide Adenosyltransferase (NMNAT)

Enzyme that converts NMN to NAD+
Genetic enhancement of NMNAT shows neuroprotective effects
Potential therapeutic target

Clinical Trial Pipeline

Adverse Effects and Safety

Generally well-tolerated across multiple clinical trials
High doses may cause: Flushing, nausea, gastrointestinal upset
Liver function: No significant hepatotoxicity observed
Long-term safety: Data still accumulating (most trials < 1 year)
Drug interactions: May interact with sirtuin inhibitors, chemotherapy agents

Contraindications

Pregnancy and breastfeeding (insufficient data)
Active malignancy (theoretical concerns about DNA repair)
Concurrent NAD+ depleting medications

Research Evidence

Preclinical Studies

Multiple preclinical studies demonstrate neuroprotective effects of NAD+ precursors:

Animal models of AD: NR supplementation improved cognitive function and reduced amyloid plaques in [APP](/entities/app-protein)/PS1 mice (Imovilli et al., Nat Commun 2020)

PD models: NMN protected dopaminergic neurons in MPTP mouse models through enhanced mitophagy

ALS models: NAD+ restoration extended survival in SOD1 G93A mice

Human Studies

NADPARK study (Brakedal et al., Cell Metab 2022): First randomized controlled trial of NR in Parkinson's disease - safe and well-tolerated

Cognitive impairment: NR improved cerebral blood flow and cognitive performance in older adults

Safety studies: Multiple Phase I trials confirm safety of NR up to 1000mg daily

Future Directions

Combination therapies: NAD+ precursors combined with mitochondrial antioxidants
Targeted delivery: Nanoparticle formulations for enhanced brain penetration
Biomarker development: NAD+ metabolites as predictive biomarkers for treatment response
Personalized medicine: Genetic variants in NAD+ metabolism genes predicting response

External Links

[ClinicalTrials.gov - NAD+ and Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative+disease&intr=nicotinamide+riboside)
[NIA Alzheimer's Disease Research Centers](https://www.nia.nih.gov/research/alzheimers-disease-research-centers)
[Michael J. Fox Foundation - Parkinson's Research](https://www.michaeljfox.org/)

Background

The study of Nad+ Precursor Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
[Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
[Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Lautrup S, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31495551/)

[Imovilli Y, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32606353/)

[Brakedal B, et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35182480/)

[Reiten R, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34046932/)

[Xie X, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32259482/)

[Hou Y, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30315278/)

[Khan NA, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32629355/)

[Sorrentino V, et al, (2017) (2017)](https://pubmed.ncbi.nlm.nih.gov/28965763/)

[Zhang H, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27475812/)

Demarin V, et al, (2020) (2020)

Pathway Diagram

The following diagram shows the key molecular relationships involving NAD+ Precursor Therapy for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-nad-precursor-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-nad-precursor-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-293d93c6510a
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nad-precursor-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

94

Outgoing

147

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

NAD+ Precursor Therapy for Neurodegenerative Diseases

NAD+ Precursor Therapy for Neurodegenerative Diseases

Introduction

NAD+ Precursor Therapy for Neurodegenerative Diseases

Introduction

Overview

Mechanism of Action

Biochemical Properties

Key Pathways Affected

Clinical Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Key Precursors

Nicotinamide Riboside (NR)

Nicotinamide Mononucleotide (NMN)

Nicotinamide (NAM)

Nicotinamide Mononucleotide Adenosyltransferase (NMNAT)

Clinical Trial Pipeline

Adverse Effects and Safety

Contraindications

Research Evidence

Preclinical Studies

Human Studies

Future Directions

See Also

External Links

Background

Allen Brain Atlas Resources

References

Pathway Diagram

💬 Discussion